Detecting Dysglycemia Using the 2015 United States Preventive Services Task Force Screening Criteria: A Cohort Analysis of Community Health Center Patients

New diabetes screening criteria in the United States do not fully diagnose all patients with dysglycemia, Matthew O'Brien and colleagues report.

Vyšlo v časopise: Detecting Dysglycemia Using the 2015 United States Preventive Services Task Force Screening Criteria: A Cohort Analysis of Community Health Center Patients. PLoS Med 13(7): e32767. doi:10.1371/journal.pmed.1002074
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pmed.1002074


New diabetes screening criteria in the United States do not fully diagnose all patients with dysglycemia, Matthew O'Brien and colleagues report.


1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. doi: 10.1016/S0140-6736(15)60692-4 26063472

2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21. doi: 10.1016/j.diabres.2011.10.029 22079683

3. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in Diabetes Among Adults in the United States, 1988–2012. JAMA. 2015;314(10):1021–9. doi: 10.1001/jama.2015.10029 26348752

4. American Diabetes Association. Standards of Medical Care in Diabetes—2015 Diabetes Care. 2015;38(Supplement I):S1–S94.

5. Knowler W, Barrett-Connor E, Fowler S, Hamman RF, Lachin J, Walker E, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. 11832527

6. Pan XR, Li G, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537–44. 9096977

7. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50. 11333990

8. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar A, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97. 16391903

9. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(2):149–57 e2. doi: 10.1016/j.amjmed.2007.09.016 18261504

10. Diabetes Prevention Program Research Group. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–30. doi: 10.2337/dc11-1468 22442395

11. American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97–111. doi: 10.2337/diaclin.33.2.97 25897193

12. Siu AL, Bibbins-Domingo K, Grossman D. Evidence-Based Clinical Prevention in the Era of the Patient Protection and Affordable Care Act: The Role of the US Preventive Services Task Force. JAMA. 2015;314(19):2021–2. doi: 10.1001/jama.2015.13154 26421503

13. Bauchner H, Fontanarosa PB, Golub RM. JAMA Welcomes the US Preventive Services Task Force. JAMA. 2016;315(4):351–2. doi: 10.1001/jama.2015.18448 26813207

14. Siu AL. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015;163(11):861–8. doi: 10.7326/M15-2345 26501513

15. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates and Its Burden in the United States. In: The Department of Health and Human Services, editor. Atlanta, GA.2014.

16. George AM, Jacob AG, Fogelfeld L. Lean diabetes mellitus: An emerging entity in the era of obesity. World J Diabetes. 2015;6(4):613–20. doi: 10.4239/wjd.v6.i4.613 25987958

17. Coleman NJ, Miernik J, Philipson L, Fogelfeld L. Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications. 2014;28(4):500–5. doi: 10.1016/j.jdiacomp.2013.11.010 24581791

18. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311(17):1778–86. doi: 10.1001/jama.2014.3201 24794371

19. HRSA Health Center Program. Health Center Data National Program Grantee Data Full 2014 National Report Washington, D.C.: U.S. Department of Health and Human Services 2014 [cited 2016 Feb 4].

20. Laws R, Gillespie S, Puro J, Van Rompaey S, Quach T, Carroll J, et al. The Community Health Applied Research Network (CHARN) Data Warehouse: a Resource for Patient-Centered Outcomes Research and Quality Improvement in Underserved, Safety Net Populations. EGEMS (Wash DC). 2014;2(3):1–9.

21. Centers for Disease Control and Prevention. ICD-9-CM official guidelines for coding and reporting. Atlanta, GA: Centers for Medicare & Medicaid Services, 2011.

22. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39 Suppl 1:S13–22. doi: 10.2337/dc16-S005 26696675

23. Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884–90. 14532317

24. Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009;19(3):288–92. 19769011

25. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2000;23(10):1563–80. 11023153

26. Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M, et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet. 2008;372(9642):940–9. doi: 10.1016/S0140-6736(08)61404-X 18790317

27. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, et al. Screening for diabetes mellitus in adults: the utility of random capillary blood glucose measurements. Diabetes Care. 1995;18(4):463–6. 7497854

28. Chung S, Azar KM, Baek M, Lauderdale DS, Palaniappan LP. Reconsidering the age thresholds for type II diabetes screening in the U.S. Am J Prev Med. 2014;47(4):375–81. doi: 10.1016/j.amepre.2014.05.012 25131213

29. Dall TM, Narayan KM, Gillespie KB, Gallo PD, Blanchard TD, Solcan M, et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr. 2014;12:1–14.

30. Casagrande SS, Cowie CC, Fradkin JE. Utility of the U.S. Preventive Services Task Force criteria for diabetes screening. Am J Prev Med. 2013;45(2):167–74. doi: 10.1016/j.amepre.2013.02.026 23867023

31. Bullard KM, Ali MK, Imperatore G, Geiss LS, Saydah SH, Albu JB, et al. Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007–2012. PLoS ONE. 2015;10(4):e0125249. doi: 10.1371/journal.pone.0125249 25928306

32. Sheehy AM, Flood GE, Tuan WJ, Liou JI, Coursin DB, Smith MA. Analysis of guidelines for screening diabetes mellitus in an ambulatory population. Mayo Clin Proc. 2010;85(1):27–35. doi: 10.4065/mcp.2009.0289 20042558

33. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27(1):9–12. 14693958

34. Sohler N, Matti-Orozco B, Young E, Li X, Gregg EW, Ali MK, et al. Opportunistic screening for diabetes and prediabetes using hemoglobin A1C in an urban primary care setting. Endocr Pract. 2016;22(2):143–50. doi: 10.4158/EP15866.OR 26484404

35. Kiefer MM, Silverman JB, Young BA, Nelson KM. National Patterns in Diabetes Screening: Data from the National Health and Nutrition Examination Survey (NHANES) 2005–2012. J Gen Intern Med. 2014;30(5):612–8. doi: 10.1007/s11606-014-3147-8 25533392

36. Weiskopf NG, Hripcsak G, Swaminathan S, Weng C. Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform. 2013;46(5):830–6. doi: 10.1016/j.jbi.2013.06.010 23820016

37. Powell H, O'Connor K, Greenberg D. Adherence to the U.S. Preventive Services Task Force 2002 osteoporosis screening guidelines in academic primary care settings. J Womens Health (Larchmt). 2012;21(1):50–3.

38. Ross JS, Forsyth BA, Rosenbaum JR. Brief report: Housestaff adherence to cervical cancer screening recommendations. J Gen Intern Med. 2006;21(1):68–70. 16423127

39. Nelson W, Moser RP, Gaffey A, Waldron W. Adherence to cervical cancer screening guidelines for U.S. women aged 25–64: data from the 2005 Health Information National Trends Survey (HINTS). J Womens Health (Larchmt). 2009;18(11):1759–68.

40. Shippee ND, Mullan RJ, Nabhan M, Kermott CA, Hagen PT, Rhodes DJ, et al. Adherence to preventive recommendations: experience of a cohort presenting for executive health care. Popul Health Manag. 2012;15(2):65–70. doi: 10.1089/pop.2011.0029 22092188

41. Gusmano MK, Fairbrother G, Park H. Exploring the limits of the safety net: community health centers and care for the uninsured. Health Aff (Millwood). 2002;21(6):188–94.

42. Dallo FJ, Weller SC. Effectiveness of diabetes mellitus screening recommendations. Proc Natl Acad Sci USA. 2003;100(18):10574–9. 12925739

43. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519–27. 12020332

44. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan—2015. Endocr Pract. 2015;21 Suppl 1:1–87. doi: 10.4158/EP15672.GL 25869408

45. Diabetes UK. Early identification of people with, and at high risk of Type 2 diabetes and interventions for those at high risk London, United Kingdom: Diabetes UK.; 2015 [cited 2016 May 2].

46. Gopalan A, Lorincz IS, Wirtalla C, Marcus SC, Long JA. Awareness of Prediabetes and Engagement in Diabetes Risk-Reducing Behaviors. Am J Prev Med. 2015.

47. Okie S. Immigrants and health care—at the intersection of two broken systems. N Engl J Med. 2007;357(6):525–9. 17687126

48. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004;27(7):1798–811. 15220270

49. Aschner P, Aguilar-Salinas C, Aguirre L, Franco L, Gagliardino JJ, de Lapertosa SG, et al. Diabetes in South and Central America: an update. Diabetes Res Clin Pract. 2014;103(2):238–43. doi: 10.1016/j.diabres.2013.11.010 24439209

50. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–101. doi: 10.1056/NEJMoa0908292 20335585

51. Gujral UP, Narayan KM, Pradeepa RG, Deepa M, Ali MK, Anjana RM, et al. Comparing Type 2 Diabetes, Prediabetes, and Their Associated Risk Factors in Asian Indians in India and in the U.S.: The CARRS and MASALA Studies. Diabetes Care. 2015;38(7):1312–8. doi: 10.2337/dc15-0032 25877810

52. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart. 2008;94(11):1376–82. doi: 10.1136/hrt.2008.147306 18519551

53. Schiff GD, Bates DW. Can electronic clinical documentation help prevent diagnostic errors? N Engl J Med. 2010;362(12):1066–9. doi: 10.1056/NEJMp0911734 20335582

54. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care. 2011;34(2):518–23. doi: 10.2337/dc10-1546 21270207

Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine

2016 Číslo 7
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle

Zvýšte si kvalifikáciu online z pohodlia domova

Hereditární TTR amyloidóza – vzácné, nebo jen neodhalené onemocnění? 2. díl
nový kurz

Eozinofilní granulomatóza s polyangiitidou

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Všetky kurzy
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.


Nemáte účet?  Registrujte sa